Photodynamic Therapy Using IR-783 Liposomes for Advanced Tongue and Breast Cancers in Humans
- PMID: 39728163
- PMCID: PMC11678438
- DOI: 10.3390/jfb15120363
Photodynamic Therapy Using IR-783 Liposomes for Advanced Tongue and Breast Cancers in Humans
Abstract
Photodynamic therapy (PDT) is a minimally invasive treatment that elicits tumor apoptosis using laser light exclusively applied to the tumor site. IR-783, a heptamethine cyanine (HMC) dye, impedes the proliferation of breast cancer cells, even without light. Although studies have investigated the efficacy of IR-783 in cell and animal studies, its efficacy in clinical settings remains unknown. Therefore, we aimed to determine the efficacy of PDT using IR-783 liposomes. An HMC dye, excited by long-wavelength infrared light and with high tissue permeability, was used for PDT after liposomization to enhance tumor tissue accumulation. PDT was performed using IR-783 in two patients with either tongue or breast cancer, one each. IR-783 liposomes inhibited cell proliferation in tongue cancer cells even when not excited by light. Tumor size was markedly reduced in both cases, with no significant adverse events. Furthermore, the patient with tongue cancer exhibited improved respiratory, swallowing, and speech functions, which were attributed not only to the shrinkage of the tumor but also to the improvement in airway narrowing. In conclusion, PDT using IR-783 liposomes effectively reduces tumor size in tongue and breast cancers.
Keywords: IR-783; breast cancer; heptamethine cyanine dyes; indocyanine green; liposome; lung cancer cells; photodynamic therapy; tongue cancer.
Conflict of interest statement
Shintarou Kimura, Yumi Hirasawa and Tomoko Katagiri are employees of StateArt Inc., Tokyo, Japan. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.Photodiagnosis Photodyn Ther. 2014 Jun;11(2):193-203. doi: 10.1016/j.pdpdt.2014.02.001. Epub 2014 Mar 19. Photodiagnosis Photodyn Ther. 2014. PMID: 24657627
-
Near-Infrared Fluorescent Heptamethine Cyanine Dyes for COX-2 Targeted Photodynamic Cancer Therapy.ChemMedChem. 2022 May 4;17(9):e202100780. doi: 10.1002/cmdc.202100780. Epub 2022 Feb 17. ChemMedChem. 2022. PMID: 35128814
-
Photodynamic therapy with paclitaxel-encapsulated indocyanine green-modified liposomes for breast cancer.Front Oncol. 2024 Mar 7;14:1365305. doi: 10.3389/fonc.2024.1365305. eCollection 2024. Front Oncol. 2024. PMID: 38515576 Free PMC article.
-
Potential of Cyanine Derived Dyes in Photodynamic Therapy.Pharmaceutics. 2021 May 31;13(6):818. doi: 10.3390/pharmaceutics13060818. Pharmaceutics. 2021. PMID: 34072719 Free PMC article. Review.
-
[History of photodynamic therapy--past, present and future].Gan To Kagaku Ryoho. 1996 Jan;23(1):8-15. Gan To Kagaku Ryoho. 1996. PMID: 8546474 Review. Japanese.
References
-
- Klement R.J. Cancer as a global health crisis with deep evolutionary roots. Glob. Transit. 2024;6:45–65. doi: 10.1016/j.glt.2024.01.001. - DOI
-
- Kataoka H., Hayashi N., Tanaka M., Kubota E., Yano S., Joh T. Tumor affinity photosensitizers for photodynamic therapy. J. Jpn. Soc. Laser Surg. Med. 2015;36:159–165. doi: 10.2530/jslsm.jslsm-36_0024. - DOI
LinkOut - more resources
Full Text Sources